We aimed to identify a signature comprising N6-methyladenosine (m6A)-related long non-coding RNAs (lncRNAs) and molecular subtypes associated with breast cancer (BRCA).We obtained data of BRCA samples from The Cancer Genome Atlas Sesame Oil / Spreads database.The m6A-related lncRNA prognostic signature (m6A-LPS) included 10 lncRNAs previously identified as prognostic m6A-related lncRNAs and was constructed using integrated bioinformatics analysis and validated.Accordingly, a risk score based on the m6A-LPS signature was established and shown to confirm differences in survival between high-risk and low-risk groups.
Three distinct genotypes were identified, whose characteristics included features of the tumor immune microenvironment in each subtype.Our results indicated that patients in Cluster 2 might have a worse prognostic outcome than those in other clusters.The three genotypes and risk subgroups were enriched in different biological processes and pathways, respectively.We then constructed a competing endogenous RNA network based on the prognostic m6A-related lncRNAs.
Finally, we validated the expression levels of target lncRNAs in 72 clinical samples.In summary, the m6A-LPS and the potentially novel genotype may provide a theoretical Anklets basis for further study of the molecular mechanism of BRCA and may provide novel insights into precision medicine.